From research grants, to exciting discoveries and treatment breakthroughs, read the latest research news from the Melanoma Institute Australia team as we work tirelessly towards our goal of zero deaths from melanoma.
Breakthrough melanoma treatment approved to be listed on PBS
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma will soon be listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
NHMRC grants for UNCUT and Automate Me clinical trials
Prestigious National Health and Medical Research Council (NHMRC) grants have been awarded for two clinical trials aiming to improve the accuracy of skin cancer diagnosis in Australia.
MIA clinicians & researchers share latest results at ASCO25
Read more about MIA clinicians and researchers in Chicago for ASCO25 - the American Society of Clinical Oncology Annual Meeting - to share latest research and clinical trial results with international colleagues.
Public consultation on Melanoma Clinical Guidelines
Melanoma Institute Australia and Cancer Council Australia are conducting a review of the clinical practice guidelines for the diagnosis and management of melanoma. The second phase is now available for review, by clinicians and the community, until 29 August 2025.
Minimising surgery and drug intervention
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
MIA awarded prestigious NHMRC grant
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
Addressing fear of cancer recurrence
A study has been released investigating the effectiveness of a Melanoma Care Program for patients with early-stage melanoma with varying degrees of fear of cancer recurrence after treatment of their primary melanoma.
Global accuracy of MIA risk tool predicting sentinel node metastasis
The extensive global use of MIA’s online tool for estimating the risk of nodal metastasis in newly diagnosed melanoma patients has prompted an international study to validate its accuracy & improve its precision across diverse populations worldwide.
Leading MIA researchers and clinicians share latest advances in Athens
MIA researchers and clinicians attended the World Congress of Melanoma, held in conjunction with the EADO Congress, in Athens.
Early career fellowship for Dr Rebecca Simpson
MIA researcher Dr Rebecca Simpson has been awarded a CINSW 2024 Early Career Fellowship which supports early & mid-career researchers through the development of research & leadership skills & innovative approaches to research.
First step to develop Roadmap for Targeted Skin Cancer Screening Program
We are excited to commence the work to develop the Roadmap for a National Targeted Skin Cancer Screening Program, and proud to be leading such an important endeavour for the Australian community.
From just 16 weeks’ survival to long term disease control
Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.